19 completed, 5 terminated, 2 withdrawn, 1 active not recruiting. 15 Phase 1, 12 Phase 2, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 9, Terminated 2, Withdrawn 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 12 | Completed 8, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 3 | 7 | Completed 6, Terminated 1 |
Follow Marqibo: new trials by email Literature Review of Marqibo trials Research Report on Marqibo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies Etoposide, Doxorubicin, Cyclophosphamide - B-cell Lymphoma, Burkitt Lymphoma | Phase 1 | Active not recruiting | Medical College of Wisconsin | 11 | 2023-01-26 | 2026-10-14 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Rituximab, Etoposide, Copanlisib - Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2022-03-24 | 2024-07-09 |
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-01-21 | 2022-01-28 | |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients Vincristine Sulfate Liposome, CHOP, R-CHOP - Hematologic Diseases | Phase 1 | Unknown | Acrotech Biopharma Inc. | 56 | 2020-08-15 | 2020-04-16 |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Bortezomib, Clofarabine, Cyclophosphamide - Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 42 | 2017-08-09 | 2026-08-10 |
| Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Lenalidomide, Rituximab, Prednisone - Primary Effusion Lymphoma, B-Cell Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2017-07-03 | 2026-11-12 |
| Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma Rituximab, Bendamustine, Vincristine sulfate liposome injection - Lymphoma, Non-Hodgkin, Lymphoma, Follicular | Phase 1 | Completed | Brown University | 11 | 2017-05-10 | 2023-02-09 |
| Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy Marqibo - ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 29 | 2017-01-31 | 2025-10-22 |
| Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Laboratory Biomarker Analysis, Pharmacological Study, Vincristine Sulfate Liposome - Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia | Phase 1 | Withdrawn | Northwestern University | 2016-08-01 | 2016-12-15 | |
| Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Vincristine Sulfate Liposome, Laboratory Biomarker Analysis - Recurrent Adult Acute Myeloid Leukemia | Phase 2 | Terminated | Wake Forest University Health Sciences | 5 | 2015-06-05 | 2019-08-14 |
| Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Rituximab, Imatinib, Cyclophosphamide - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 31 | 2013-03-05 | 2022-09-27 |
| A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Vincristine Sulfate Liposomes Injection (VSLI), Vincristine Sulfate Injection (VSI) - Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 26 | 2012-03-01 | 2021-09-09 |
| To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Marqibo - Sarcoma, Neuroblastoma | Phase 1 | Completed | Acrotech Biopharma Inc. | 22 | 2010-09-01 | 2020-01-18 |
| Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Cixutumumab, Cyclophosphamide, Dactinomycin - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 175 | 2010-01-01 | 2017-08-29 |
| Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate - Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma | Phase 3 | Completed | Children's Oncology Group | 166 | 2009-12-07 | 2022-04-28 |
| Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia cyclophosphamide, cytarabine, dexamethasone - Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 11 | 2009-06-01 | 2023-01-06 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 148 | 2009-03-01 | 2017-01-27 |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas Rituximab, Etoposide, Siplizumab - T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2009-01-13 | 2021-11-03 |
| Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin - Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma | Phase 3 | Completed | Children's Oncology Group | 665 | 2007-11-05 | 2022-04-28 |
Showing 20 of 29. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Burkitt Lymphoma (6) · Leukemia (4) · Lymphoma, Large B-Cell, Diffuse (4) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Extranodal NK-T-Cell (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell, Peripheral (2) · Neuroblastoma (2)
Children's Oncology Group (7) · National Cancer Institute (NCI) (7) · Acrotech Biopharma Inc. (5) · M.D. Anderson Cancer Center (2) · Brown University (1) · Medical College of Wisconsin (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · Spectrum Pharmaceuticals, Inc (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Wake Forest University Health Sciences (1)
United States (28) · Canada (10) · Australia (9) · Puerto Rico (6) · New Zealand (5) · Israel (3) · Switzerland (3) · India (1) · United Kingdom (1)
Mark J Roschewski, M.D. (2) · Adam J Olszewski, MD (1) · Agop Bedikian, MD (1) · Allen Wayne (1) · Brandon Hayes-Lattin (1) · Deborah Thomas, MD (1) · Debra Friedman (1) · Elias Jabbour, MD (1) · Elizabeth A Mullen (1) · Elizabeth Raetz, MD (1) · Eunice S Wang (1) · Gareth Morgan, Prof. (1) · Julie R Park (1) · Kara Kelly, MD (1) · Lawrence Kaplan, MD (1)
PMID 37505794, PMID 23393050, PMID 23574119, PMID 24224624, PMID 25024303, PMID 25311218, PMID 28419486, PMID 29032710, PMID 29296710, PMID 29659330, PMID 29748435, PMID 30125215, PMID 30957229, PMID 31449468, PMID 31454045, PMID 32530765, PMID 33512412, PMID 34432874, PMID 34662378, PMID 35580298, PMID 35641232, PMID 35882475, PMID 37933882, PMID 39937083, PMID 39969278, PMID 40036726, PMID 40135712
U10CA098543 (9), U10CA180886 (4), P30CA012197 (1), P30CA060553 (1), U01CA097452 (1)